SHANGHAI – In China's evolving regulatory and pricing environment, Sciclone Pharmaceuticals Inc., of Foster City, Calif., has managed to keep growing its bottom line with lead drug Zadaxin (thymalfasin), an imported drug manufactured in Italy for the treatment of hepatitis B, hepatitis C, certain cancers and as a vaccine adjuvant. In the first quarter, the firm raked in $33.6 million, growing 7 percent from the year prior and beating China's average pharma growth rate by 1 percent (estimated by Sciclone to be 6 percent).
SUZHOU, China – China's economy is evolving rapidly and the new normal of slower growth has arrived. But don't tell the folks in China's life sciences industry, one of the few bright spots in an otherwise messy time of economic transition. The sector enjoyed what Greg Scott, founder of Chinabio LLC calls "explosive growth" last year.
SHANGHAI – In China's evolving regulatory and pricing environment, Sciclone Pharmaceuticals Inc., of Foster City, Calif., has managed to keep growing its bottom line with lead drug Zadaxin (thymalfasin), an imported drug manufactured in Italy for the treatment of hepatitis B, hepatitis C, certain cancers and as a vaccine adjuvant. In the first quarter, the firm raked in $33.6 million, growing 7 percent from the year prior and beating China's average pharma growth rate by 1 percent.
SHANGHAI – Several weeks ago a 21-year-old man named Wei Zexi, diagnosed with terminal synovial sarcoma, a rare form of cancer of the soft tissue, died. In the weeks since his death, public debate and outrage have hit upon various elements of his story, illustrating a volatile mix of distrust in online transparency, lax oversight of regulations governing cell treatments and commonplace greed. It is also giving immunotherapy, a promising form of cancer treatment, a bad reputation in China.
SHANGHAI – Several weeks ago a 21-year-old man named Wei Zexi, diagnosed with terminal synovial sarcoma, a rare form of cancer of the soft tissue, died. In the weeks since his death, public debate and outrage have hit upon various elements of his story, illustrating a volatile mix of distrust in online transparency, lax oversight of regulations governing cell treatments and commonplace greed. It is also giving immunotherapy, a promising form of cancer treatment, a bad reputation in China.
SHANGHAI – An unlikely union has been forged between San Francisco-based Unity Biotechnology Inc., a biopharma focused on developing anti-aging drugs to improve healthy life span, and Ascentage Pharma Group, of Taizhou, Zhejiang, a clinical-stage firm focused on apoptosis-targeted oncology drug discovery and development.
SHANGHAI – An unlikely union has been forged between San Francisco-based Unity Biotechnology Inc., a biopharma focused on developing anti-aging drugs to improve healthy life span, and Ascentage Pharma Group, of Shanghai, a clinical-stage firm focused on apoptosis-targeted oncology drug discovery and development.
SHANGHAI – Hua Medicine Ltd. has raised $50 million in a series C investment led by China-based Harvest Investments. Hua is now preparing a phase III trial for its lead candidate, HMS5552, a fourth generation glucokinase activator (GKA) for type 2 diabetes.
SHANGHAI – London-based Glaxosmithkline plc is on the hunt for new ways to treat brain diseases and has found an academic partner in the Sanford Burnham Prebys Medical Discovery Institute (SBP), of La Jolla, Calif.
SHANGHAI – Hua Medicine Ltd. has raised $50 million in a series C investment led by China-based Harvest Investments. Hua is now preparing a phase III trial for its lead candidate, HMS5552, a fourth generation glucokinase activator (GKA) for type 2 diabetes.
